Wolfson Group, a Scotland-based international consumer wellness company, is drawing attention to the expanding range of weight management options available to U.S. consumers. The company’s announcement comes as a June 2026 report from PwC shows that 21% of U.S. households included a current GLP-1 user as of May 2026, up from just 9% in January 2025. That rapid adoption of prescription medications is reshaping the weight management landscape, but Wolfson Group argues that nutrition, physical activity and non-prescription wellness products remain central to how many people approach weight management.
The company participates in the non-prescription category through PhenQ, its established consumer wellness brand. PhenQ is available to U.S. consumers through Amazon and, more recently, through OneLavi.com. The added distribution channel reflects Wolfson Group’s broader U.S. strategy of developing multiple retail paths while supporting its portfolio of wellness brands.
“The weight management market is evolving, and consumers have more choices than ever before,” said the founder and CEO of Wolfson Group. “Prescription medications have become an important part of the conversation, but nutrition, physical activity and everyday lifestyle habits remain central to how people think about managing their weight. Our focus is on serving consumers in the non-prescription wellness market.”
The company emphasizes that non-prescription products like PhenQ are distinct from prescription GLP-1 medications and should not be viewed as substitutes for prescribed medical treatments. Wolfson Group believes the growing visibility of GLP-1s creates opportunities for greater consumer education about the different categories of products and services available, their intended purposes and the importance of informed decisions.
Wolfson Group’s portfolio spans weight management, cognitive wellness, gut health and men’s wellbeing, with brands including PhenQ and others available to U.S. consumers through Amazon. The company continues to pursue additional U.S. retail opportunities following its participation in the September ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida.
The implications of Wolfson Group’s announcement are twofold. First, as GLP-1 use more than doubles in U.S. households, the weight management market is becoming more segmented, with prescription and non-prescription categories coexisting rather than competing directly. Second, the company’s expansion into additional online channels signals that non-prescription wellness brands are seeking wider accessibility to meet consumer demand. By stressing consumer education and responsible communication, Wolfson Group is positioning itself to serve adults who view weight management as part of a broader lifestyle routine, while acknowledging that prescription medications now play a significant role in the national conversation.
